Phase 1Recruiting
The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery
- Sponsor
- The University of Texas Health Science Center at San Antonio (Academic or other)
- Enrolment
- 150 planned
- Conditions
- Non-Diabetic
- Interventions
- REMD-477 versus Placebo; Exogenous glucagon versus saline infusion
- Ages
- adults, older adults
- Registry
- NCT07212868
From the registry
The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism with glucagon infusion and glucagon receptor blockade. We use an investigational drug called REMD 477. "Investigational" means that the has not yet been approved by the U.S. Food \& Drug Administration (FDA). REMD-477 is a monoclonal antibody (an antibody made by cloning a unique white blood cell) that blocks the effect of glucagon.
Primary outcomes
- Glycemic response to meal ingestion
- Endogenous glucose production (EGP) during clamp studies